Inclusion Criteria:

- Diagnosis of platinum-sensitive recurrence of epithelial ovarian cancer, primary
peritoneal cancer, or fallopian tube cancer

- The following histologic subtypes are eligible: papillary serous, endometrioid,
mucinous, clear cell, adenocarcinomas, transitional, and mixtures of the above.

- At least one measurable lesion according to RECIST criteria via CT or MRI scan

- Received a platinum-containing regimen at initial diagnosis

- ECOG performance status of 0,1 or 2

- 18 years of age or older

- Life expectancy of greater than 12 weeks

- WBC > 1,500/mm3

- Neutrophils > 1,500/mm3

- Platelets > 100,000/mm3

- Total Bilirubin < 1.5 ULN

- Calculated creatinine clearance > 45 ml/min

- ALT/AST < 3 x ULN (no liver mets) ALT/AST < 5 x ULN (with liver mets)

- Complete recovery from completion of previous chemotherapy or biologic therapy

- Negative pregnancy test and agree to practice effective method of birth control

Exclusion Criteria:

- Patients with sarcomatous, stromal, or germ cell elements

- Prior pelvic radiotherapy > 25% of bone marrow

- Uncontrolled medical problem that in the opinion of the investigator would preclude
safe administration of the study drugs

- Past history of bone marrow transplantation or stem cell support

- Known history of CNS metastasis unless the patient has had treatment with surgery or
radiation therapy, is neurologically stable, and does not require oral or intravenous
corticosteroids or anticonvulsants

- Prior malignancy except adequately treated carcinoma in situ of the uterine cervix,
incidental stage I endometrial cancer, basal cell or squamous cell skin cancer or
breast cancer (invasive or ductal carcinoma in situ) of which the patient has been
disease-free for at least five years

- Routine prophylactic use of G-CSF or GM-CSF or blood transfusions within 2 weeks

- Clinically significant cardiac disease as defined by: history of unstable angina
within 6 months; history of symptomatic ventricular arrhythmias; history of
congestive heart failure; history of myocardial infarction within 6 months

- Uncontrolled hypercalcemia or diabetes mellitus

- Any signs of intestinal obstruction with bowel function and/or nutrition

- Grade 2 or greater peripheral neuropathy

- Participation in an investigational study within three weeks

- History of anaphylactic shock to prior platinum chemotherapy

- History of psychiatric disability or other central nervous system disorder